Riechardt, Aline I.
Klein, Julian P.
Cordini, Dino
Heufelder, Jens
Rehak, Matus
Seibel, Ira
Joussen, Antonia M.
Article History
Received: 18 May 2017
Revised: 28 January 2018
Accepted: 2 February 2018
First Online: 20 February 2018
Compliance with ethical standards
:
: A.I. Riechardt: reimbursements of travel expense: EURETINA 2015/Novartis. J.P. Klein states that there are no conflicts of interest. D. Cordini states that there are no conflicts of interest. J. Heufelder states that there are no conflicts of interest. M. Rehak: board membership: Novartis, Allergan, Alimera, speaker honoraria: Novartis Bayer, Allergan, Alimera. I. Seibel states that there are no conflicts of interest. Prof. A. M. Joussen states that there are no conflicts of interest. The authors declare that they have no conflict of interest.
: This study was approved by the institutional review board of the Charité-Universitätsmedizin Berlin, Berlin, Germany, and was in accordance with the tenets of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.